✉news HealthFitness first seen 14 h ago, last 12 h ago, peak #17
CSL may spend up to $2.2 billion on Swiss biotech deal
Original: CSL could spend up to $2.2b on drug deal with Swiss biotech start-up
Australian biotech giant CSL is reported to be weighing a deal worth up to $2.2 billion with a Swiss biotech start-up, according to the Australian Financial Review. The arrangement would centre on rights to a drug candidate, adding to CSL's pipeline as it looks for new growth areas beyond its established plasma-based therapies.
Why now: The size of the potential investment and CSL's search for pipeline growth make the reported deal newsworthy for investors and the biotech sector.
Rank over time, top of the chart is #1. 2 snapshots from 14 h ago to 12 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/1074291